Canadian Journal of General Internal Medicine

SGLT-2 inhibitors have proven to be an effective treatment for glycemic control in type 2 diabetes mellitus. The indications for SGLT-2 have been expanding beyond glycemic control and now include chronic kidney disease and heart failure. These broadened indications mean more GIM physicians will be prescribing this class of medication to help improve the quality of life in patients. With this in mind, we are very pleased to publish this special supplement to the Canadian Journal of General Internal Medicine on the topic of SGLT-2 Therapy and its recent advancements and usage. These articles have been written by leading specialists, providing the reader with practical, clinically relevant and timely information. Special thanks to Eli Lilly Canada and Boehringer Ingelheim Canada for their unrestricted support of this special issue. Both companies had no input on the content, scope focus or author selection and were not involved in any review process.